HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Phase A, individuals will obtain distinctive doses and schedules of oral ABBV-744 tablet to recognize Protected dosing regimen. Additional contributors might be enrolled for the discovered monotherapy dosign routine. In Segment B, members will obtain oral ruxolitinib and ABBV-744 will probably be given as "increase-on" therapy. In Segment C, ind